Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 329
- Registration Number
- NCT02586025
- Locations
- 🇨🇳
Taipei Medical University ?Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳China Medical University Hospital; Surgery, Taichung, Taiwan
🇹🇭Bhumibol Adulyadej Hospital; Medicine, Bangkok, Thailand
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02536339
- Locations
- 🇺🇸
Temple Cancer Center; Oncology, Philadelphia, Pennsylvania, United States
🇺🇸Methodist Hospital Research Institute, Houston, Texas, United States
🇺🇸Dana Farber Cancer Inst., Boston, Massachusetts, United States
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 102
- Registration Number
- NCT02530424
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milano, MI, Italy
🇮🇹Policlinico Sant'Orsola Malpighi, Bologna, BO, Italy
🇮🇹Azienda Ospedaliero Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, FE, Italy
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 370
- Registration Number
- NCT02514681
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
🇯🇵Kumamoto University Hospital, Kumamoto City, Kumamoto, Japan
🇯🇵Aichi Cancer Center, Chikusa-ku, Aichi, Japan
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02507375
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 79
- Registration Number
- NCT02491892
A Study of Pertuzumab in Participants With Prostate Cancer
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT02480010
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02445586
- Locations
- 🇮🇳
Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India
🇮🇳Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India
🇮🇳Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 120
- Registration Number
- NCT02436993
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.